MicroRNAs as a New Target for Alzheimer's Disease Treatment

Basit Öğe Kaydı
dc.contributor.authorShademan, Behrouz
dc.contributor.authorAvci, Cigir Biray
dc.contributor.authorKaramad, Vahidreza
dc.contributor.authorSogutlu, Fatma
dc.contributor.authorNourazarian, Alireza
dc.date.accessioned2024-08-31T07:49:41Z
dc.date.available2024-08-31T07:49:41Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractAlzheimer's disease (AD) is the most common progressive neurodegenerative disease associated with advanced age. It is characterized by cognitive decline and memory loss and accounts for most cases of dementia in older people. AD can be rooted in genetic, epigenetic, or environmental causes. No drugs or other therapeutic agents prevent or delay AD progression. MicroRNAs (miRNAs) are short and uncoded RNAs that can bind to 200 RNAs approximately. By inhibiting or destroying specific messenger RNAs (mRNAs), they control gene expression and broadly affect cellular functions. MiRNAs play important roles in regulating neuronal growth, neuronal differentiation, dendritic spine morphology, and synaptic flexibility in the nervous system. The expression levels of miRNAs are changed in neurological diseases, including AD, suggesting that they play an essential role in the pathogenesis of the disease. Therefore, targeting disrupted miRNAs may be a novel therapeutic approach against AD and offers multiple solutions, including harnessing the beneficial effects of beta-amyloid, reducing tau protein, reducing neuronal cell death, and protecting synapses in AD.en_US
dc.description.sponsorshipEGE University, Turkey Department of Medical Biologyen_US
dc.description.sponsorshipWe thank EGE University, Turkey Department of Medical Biology for their contributions.en_US
dc.identifier.doi10.2174/2211536611666220928154015
dc.identifier.endpage12en_US
dc.identifier.issn2211-5366
dc.identifier.issn2211-5374
dc.identifier.issue1en_US
dc.identifier.pmid36173083en_US
dc.identifier.startpage3en_US
dc.identifier.urihttps://doi.org/10.2174/2211536611666220928154015
dc.identifier.urihttps://hdl.handle.net/11454/104960
dc.identifier.volume12en_US
dc.identifier.wosWOS:001191408200001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBentham Science Publ Ltden_US
dc.relation.ispartofMicrornaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240831_Uen_US
dc.subjectMicrornaen_US
dc.subjectAlzheimer's Diseaseen_US
dc.subjectTau Proteinen_US
dc.subjectNeurodegenerative Diseaseen_US
dc.subjectHuntington's Diseaseen_US
dc.subjectParkinson's Diseaseen_US
dc.titleMicroRNAs as a New Target for Alzheimer's Disease Treatmenten_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu